Ku­ra’s stock jumps on PhIb read­out; FDA lifts hold on IN­mune Bio pro­gram; Nanobi­otix’s $20M mile­stone

Plus, news about Iterum Ther­a­peu­tics, As­tria Ther­a­peu­tics, Aqemia, Ake­bia Ther­a­peu­tics, Tour­ma­line Bio and Ve­ra Ther­a­peu­tics:

Ku­ra On­col­o­gy’s pos­i­tive PhIb read­out: The com­pa­ny is test­ing its in-house menin in­hibitor drug, ziftomenib, in com­bi­na­tion with dif­fer­ent stan­dards of care in 20 pa­tients with acute myeloid leukemia. All five pa­tients re­ceiv­ing one form of stan­dard of care plus ziftomenib achieved a com­plete re­sponse, while 8 of 15 who re­ceived a dif­fer­ent stan­dard of care reg­i­men al­so re­spond­ed to the com­bo. There were no dif­fer­en­ti­a­tion syn­drome events re­port­ed, Ku­ra said. As of the Jan. 11 da­ta cut­off, 16 of 20 pa­tients re­main in the tri­al. Ku­ra’s stock $KU­RA gained about 14% on Tues­day morn­ing. — Max Gel­man

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER